News Cheaper Soliris biosimilars reach the US market The first biosimilars of AstraZeneca/Alexion's blockbuster complement C5 inhibitor Soliris have been launched in the US at a discount to the brand.
News First biosimilar fast-acting insulin reaches US market Sanofi has claimed FDA approval for the first biosimilar of Novo Nordisk's rapid-acting insulin analogue Novolog.
News Trump tariffs 'would strain the pharma supply chain' Pharma organisations in the US have said that Trump's tariffs plan could drive up the cost of generics, block supply chains and worsen drug shortages.
R&D Life Sciences Industry Report - Part 7 The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
Patients Pharmacy benefits: Lessons from 2024 and what lies ahead for... The healthcare industry experienced a rollercoaster of a year in 2024, with pharmacy benefits undergoing significant shifts.
Market Access Why the NHS needs to maximise the impact of biosimilars Ensuring the long-term sustainability of the NHS increasingly appears to be an unfathomable prospect.
Patients Prevention for a healthier, more productive society During Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh spoke with David Gillen, chief medical officer at Norgine.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl